Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development

Patrick Ming-Kuen Tang1,2,*, Shuang Zhou2,3,4,*, Xiao-Ming Meng2,*, Qing-Ming Wang2, Chun-Jie Li2, Guang-Yu Lian2, Xiao-Ru Huang2, Yong-Jiang Tang2, Xin-Yuan Guan5, Bryan Ping-Yen Yan2, Ka-Fai To1 & Hui-Yao Lan1,2

TGF-β is known to influence tumour progression. Here we report an additional role of Smad3 in the tumour microenvironment regulating cancer progression. Deletion or inhibition of Smad3 in the tumour microenvironment suppresses tumour growth, invasion and metastasis in two syngeneic mouse tumour models. Smad3−/− bone marrow gives rise to an expanded NK cell population with enhanced tumour-suppressive activities in vivo, and promotes differentiation of NK cells ex vivo. We identify E4BP4/NFIL3 as a direct Smad3 target gene critical for NK cell differentiation. Smad3 suppresses transcription of IFN-γ via E4BP4 in a T-bet independent manner. Therefore disruption of Smad3 enhances both the E4BP4-mediated NK cell differentiation and anti-cancer effector functions in vivo and in vitro. Furthermore, systemic treatment with a Smad3 inhibitor SIS3 effectively suppresses cancer progression. In summary, suppression of NK cell-mediated immunosurveillance via the Smad3-E4BP4 axis contributes to cancer progression. We propose targeting Smad3-dependent tumour microenvironment may represent an effective anti-cancer strategy.
Cancer progression is dependent not only on the characteristics of cancer cells but also on the tumour microenvironment1,2. Transforming growth factor-β (TGF-β) has been suggested to play a suppressive role in carcinogenesis, but paradoxically cancer cells also produce TGF-β to support the tumour development3–5. Cancer cell-derived TGF-β can promote tumour growth by triggering angiogenesis, epithelial–mesenchymal transition and the matrix metalloproteinase (MMP) system for ECM degradation6–8. There is an increasing evidence that pro-tumorigenic microenvironment is promoted by TGF-β signalling9–12. Smad3 is a key mediator of canonical TGF-β signalling pathway and plays an important role in the TGF-β1-mediated transcriptional regulation13. Smad3-deficient mice exhibit impaired mucosal immunity and diminished T-cell responses to TGF-β8,10. The lack of Smad3 resulted in severe graft-versus host disease by promoting Th1 differentiation and granulocyte-mediated tissue injury11. Smad3 can bind to the Foxp3 enhancer for the development of regulatory T (Treg) cells and differentially regulates the induction of Treg and Th17 immune responses12,13. Thus mice lacking Smad3 have impaired Treg development14. TGF-β has a suppressive role in the cytolytic activity, especially on the interferon responsiveness of natural killer (NK) cells in vitro15,16. In addition, Trotta et al. elucidated that TGF-β/Smad signalling can suppress CD16-mediated interferon-gamma (IFN-γ) production in NK cells via reducing T-bet expression. Smad3 mutant mice were reported to develop metastatic colorectal cancer,18 which may be related to chronic inflammation19,20. In contrast, mice lacking Smad3 were recently suggested to be resistant to chemical-induced skin carcinogenesis by Li et al.21. The discrepancy among the studies underlie the importance in further delineation of the mechanism of TGF-β/Smad signalling in tumour progression. Nevertheless, these studies suggested that Smad3 could be an important checkpoint for TGF-β signalling in the tumour microenvironment.

In the present study, we demonstrate the crucial role of Smad3-dependent tumour microenvironment in cancer progression by using two well-established syngeneic mouse tumour models. Mice lacking Smad3 are protected against tumour growth, invasion, metastasis and death. NK cell population in the Smad3−/− tumour microenvironment is dramatically expanded. This observation led us to identify that E4BP4 (Nfl3), one of the master transcription factors for NK cell differentiation22–24, is a direct Smad3 target gene. Thus TGF-β/Smad3 signalling facilitates cancer progression by suppressing NK cell production via downregulating E4BP4. The crucial role of Smad3 is further supported by animal experiments with reconstitution of GFP+/Smad3−/− bone marrow on Smad3+/+/ mice and adoptive transfer of Smad3−/−/NK1.1+/ mice into B16F10 tumour-bearing NOD/SCID mice. Furthermore, systemic treatment with a Smad3 inhibitor can suppress cancer progression by reversing the tumour promoting to an anticancer microenvironment in vivo. Therefore, our findings reveal the unexplored role of Smad3 in NK cell immunity and tumour microenvironment. The therapeutic potential of Smad3-targeted therapy for cancer treatment is also implicated.

**Results**

Smad3 is essential for cancer progression in mice. As TGF-β/Smad signalling has been shown to be a pro-tumorigenic factor in cutaneous melanoma and lung cancer25,26, the role of Smad3 in tumour microenvironment was investigated by using two syngeneic mouse tumour models with luciferase-expressing invasive mouse lung carcinoma (LLC-luc) or melanoma (B16F10-luc) established in Smad3−/− (deletion of exon 8 and disruption of exon 7) and their littermate Smad3+/+ mice (C57BL/6J background). During the first week after subcutaneous inoculation of LLC-luc cells, we observed almost equal tumour growth in both Smad3−/− and Smad3+/+ mice. However, in the subsequent weeks, significant tumour regression was found in Smad3−/− mice where the tumours became undetectable by macroscopic and microscopic examinations and by bioluminescence imaging at week 3 (Fig. 1a–d). In contrast, the tumours in the Smad3−/− mice grew rapidly and invasively, resulting in 40% mortality at week 3 (Fig. 1a–d). A similar pattern of cancer progression was observed in Smad3−/− and Smad3+/+ mice bearing a highly invasive melanoma cancer cell line B16F10 (Fig. 1e–g). In the B16F10 tumour-bearing Smad3−/+ mice, melanoma grew rapidly and invasively with metastasis to the lymph nodes, lung and colon, resulting in 60% mortality at week 3 (Fig. 1h and Supplementary Fig. 1). In contrast, these malignant features were absent in the tumour-bearing Smad3−/− mice in which survival rate was 100% without features of metastases (Fig. 1h and Supplementary Fig. 1). In addition, the protective effect of Smad3−/− microenvironment was further confirmed on a tumour rechallenging model (Supplementary Fig. 2A,B). These observations supported the importance of Smad3 in the tumour microenvironment for promoting tumour growth, invasion and metastasis. The supportive role of Smad3-dependent microenvironment in cancer metastasis was further examined in mouse metastatic models by intravenously (i.v.) administering LLC-luc or B16F10-luc cells into the mice. As shown in Fig. 1i–n, mice lacking Smad3 were resistant to cancer metastasis with barely detectable LLC-luc cancer cells and a few melanoma nodules in the lung. By contrast, Smad3+/+ mice developed massive lung cancer with a 100% mortality rate (Fig. 1o,p). These findings provided a clear and direct evidence for a crucial role of Smad3-dependent microenvironment in cancer progression.

Smad3 suppresses NK cell immunity in tumour-bearing mice. We next investigated the underlying mechanisms whereby mice lacking Smad3 were protected against cancer growth and metastasis. A 10-fold increase in the number of tumour-infiltrating NK1.1+ NKP46+ and NK1.1+ IFN-γ+ NK cells was found in the B16F10 tumour-bearing mice lacking Smad3 compared with the Smad3+/+ group (Fig. 2a–c). The inhibitory effect of Smad3-dependent microenvironment on NK cell population was further investigated. Native Smad3−/− mice (without tumour inoculation) showed slight increase in mature NK1.1+ CD49b+ NK cells in the bone marrow, spleen, lung and peripheral blood compared with Smad3+/+ mice (Supplementary Fig. 3A). The population of NK1.1+ CD49b+ NK cells was further increased after cancer inoculation, resulting in a 10-fold increase in NK1.1+ CD49b+ NK cells in the peripheral blood and lung and a 3-fold increase in the spleen compared with the tumour-bearing Smad3+/+ mice (Supplementary Fig. 3B,C). The increase in mature NK1.1+ NKP46+ NK cells was also observed in the tumour, spleen and blood of the B16F10-rechallenged mice lacking Smad3 (Supplementary Fig. 2C,D). In addition, deletion of Smad3 also enhanced the anticancer activities of NK cells by increasing the levels of granzyme B, interleukin (IL)-2 and IFN-γ locally within the cancer microenvironment and in the systemic circulation (Fig. 2d,e). The splenic NK cells isolated from the B16F10 tumour-bearing Smad3−/− mice also exhibited a significant increase in the ex vivo cytotoxicity against tumour cells with higher levels of INF-γ production when compared with the NK cells obtained from the tumour-bearing Smad3+/+ mice (Supplementary Fig. 4). Moreover, a marked reduction in
Figure 1 | Mice lacking Smad3 are protected from tumour progression. LLC-luc cancer cells were s.c. inoculated into Smad3+/+ and Smad3−/− mice (n = 3) and examined by bioluminescence imaging on day 21 (a), tumour volumes (b), tumour weights on day 21 (c) and the Kaplan-Meier plot of survival (d). B16F10 cells (2 × 10^5 cells per mouse) were s.c. inoculated into Smad3+/+ and Smad3−/− mice (n = 5) and examined for the growth patterns (highlighted with white circles) on day 21 (e), tumour volumes (f), tumour weights on day 21 (g) and the Kaplan-Meier plot of survival (h). LLC-luc cells (3 × 10^5 cells per mouse) were i.v. inoculated into Smad3+/+ and Smad3−/− mice (n = 5) and examined for the metastatic growth patterns in the lung by bioluminescence imaging (i), quantitative photon intensities (j) and histology on H&E-stained sections (k). B16F10 cells (3 × 10^5 cells per mouse) were i.v. inoculated in Smad3+/+ and Smad3−/− mice (n = 5) and examined for metastatic growth in the lung by macroscopic morphology (l), quantitative analysis of metastatic nodules (m) and histology on H&E-stained sections (n). Note that the metastatic B16F10 tumours in the lung are shown by the dark-black nodules grossly and the metastatic LLC or B16F10 nodules on H&E-stained sections are indicated with the white star (*). Kaplan-Meier plot of survival rates of metastatic LLC-luc (o) and B16F10 (p) tumour-bearing mice. Data represent the mean ± s.d. for groups of mice as indicated in individual experiments above. *P < 0.05, **P < 0.01 compared with tumour-bearing Smad3+/+ mice analysed by analysis of variance. Scale bars, 50 μm.

vascular endothelial growth factor (VEGF) expression, CD31+ blood vessels, CD4+ Foxp3+ Treg cells and the expression of MMP-2, MMP-9, MMP-13 and C-X-C motif chemokine receptor 4 (CXCR4) in the tumour stroma were observed in the Smad3−/− tumour microenvironment (Supplementary Figs 5 and 6). In contrast, depletion of NK cells from the tumour-bearing hosts with a neutralizing antibody restored rapid progression of the B16F10 tumour only in Smad3−/− mouse but not
Figure 2 | Smad3 facilitates cancer progression by suppressing host NK cell immunity in the tumour microenvironment. (a) Immunofluorescence detects the tumour-infiltrating NK1.1⁺, NKp46⁺ and NK1.1⁺ IFN-γ⁺ NK cells in the B16F10 tumour collected on day 7. Representative images of tumour sections stained with the antibodies recognizing NK1.1 (green, upper panel), NKp46 (green, middle panel), NK1.1 (red) and IFN-γ (green, lower panel) are shown. Nuclei were counterstained with DAPI (blue), and the percentage of positive cells in the tumour tissues of Smad3+/+ or Smad3−/− mice are shown (right panel). (b) Two-colour flow cytometry shows the population of tumour-infiltrating NK1.1⁺ CD49b⁺ cells in the B16F10 tumour. (c) Western blotting analysis detects the NKp46 expression within the tumour tissues. (d,e) Enzyme-linked immunosorbent assay analysis determines the levels of granzyme B, IL-2 and IFN-γ in the tumour tissues (d) and circulation (e). (f) Effects of NK cell depletion on cancer progression in B16F10 tumour-bearing Smad3−/− mice as determined by bioluminescent imaging, tumour volume measurement and the survival rate. Data represent mean ± s.d. for groups of 3–5 mice. *P<0.05, **P<0.01 compared with B16F10 tumour-bearing Smad3+/+ or Smad3−/− mice (a–e) or Smad3−/− mice (f) analysed by analysis of variance. Scale bars, 50 (upper panel in a) and 100 μm.
in Smad3+/+ mice in vivo (Fig. 2f and Supplementary Fig. 7). These findings suggested an inhibitory role of Smad3 in NK cell development on a systemic level and a crucial role of NK cells in the Smad3-dependent tumour microenvironment.

**Smad3 tumour microenvironment is derived from bone marrow.** We then investigated the origin of Smad3-dependent tumour microenvironment by using GFP+ Smad3−/− and GFP+ Smad3+/+ bone marrow chimeric mice bearing subcutaneous LLC-luc or B16F10-luc tumours. Our data showed that almost all stromal cells within the tumour tissue were derived from the transplanted bone marrow as recognized by their green fluorescent protein (GFP) expression (Fig. 3a). Compared with GFP+ Smad3+/+ chimeric mice, mice with GFP+ Smad3−/− bone marrow exhibited significant reduction in the tumour growth and mortality rate (Fig. 3b,c), which was again associated with a 10-fold increase in GFP+ NK1.1+ cells in the tumour microenvironment (Fig. 3a). These results suggested that Smad3 may suppress host anticancer immunity at the bone marrow compartment. The inhibitory role of Smad3 on bone marrow-derived NK cell immunity was confirmed in vitro; the cancer-killing activity of NK cells differentiated from Smad3−/− bone marrow cells was significantly higher than the Smad3+/+ control (Supplementary Fig. 8A). Interestingly, disruption of Smad3 (knockout or inhibition) facilitated NK cell maturation (NKp46−IFN-γ− cells) even in the presence of TGF-β (Supplementary Fig. 8C). Therefore, deletion of Smad3 may enhance NK cell development in bone marrow and augmentation of host anticancer immunity at the distant tumour microenvironment.

**Smad3 suppresses E4BP4-dependent NK cell maturation.** As Smad3−/− microenvironment was able to protect mice

---

**Figure 3** Smad3-dependent tumour microenvironment is derived from the bone marrow. LLC-luc or B16F10-luc cancer cells were s.c. inoculated into GFP+ Smad3+/+ and GFP+ Smad3−/− chimeric mice and examined for: (a) bone marrow-derived NK cells (GFP+ NK1.1+) in the tumour tissues by two-colour immunofluorescence; (b,c) tumour growth patterns by bioluminescent imaging, tumour volumes, tumour weights on day 21 and the survival rate of LLC (b) or B16F10 (c) tumour-bearing chimeric mice. Data represent mean ± s.d. for groups of 4–5 mice. *P < 0.05, **P < 0.01 compared with tumour-bearing Smad3+/+ chimeric mice received GFP+ Smad3−/− bone marrow transplantation analysed by analysis of variance. Scale bars, 100 μm.
against cancer progression by dramatically increasing NK cell production (Figs 1–3 and Supplementary Figs 1 and 2), we further investigate the unexplored role of Smad3 as a negative regulator in the NK cell development. Western blottings showed that deletion of Smad3 increased the expression of E4BP4 (or Nfil3), an important transcription factor for NK lineage commitment22–

24, in both bone marrow-derived and splenic NK cells from the Smad3−/− mice on Day 10 after tumour inoculation (Fig. 4a). It suggested a close link between Smad3 and NK cell development in the tumour microenvironment. To examine the inhibitory role of TGF-β1/Smad3 signalling in E4BP4, total bone marrow cells or untouched splenic NK cells from Smad3+/+ or Smad3−/− mice were stimulated with TGF-β1 for 3 h and subjected for real-time PCR analysis. As shown in Fig. 4b–d, TGF-β1 significantly suppressed the transcription of E4BP4 mRNA in Smad3+/+ bone marrow cells and splenic NK cells, which was blunted when Smad3 was genetically deleted or pharmacologically inhibited with Smad3 inhibitor (SIS3). We next investigated the functional importance of E4BP4 in Smad3-mediated suppression of NK cell development by transfecting bone marrow cells from Smad3+/+ and Smad3−/− mice with nonsense (control) or short interfering RNA (siRNA) against mouse E4BP4 (siE4BP4) and cultured under NK cell differentiation medium for 6 days. Real-time PCR detected that SIS3 treatment increased E4BP4 mRNA expression in Smad3+/+ NK cells, whereas transient knockdown with siE4BP4 resulted in significant inhibition of E4BP4 mRNA expression in bone marrow-derived Smad3+/+ and Smad3−/− NK cells as well as SIS3-treated Smad3+/+ NK cells (Supplementary Fig. 9). Strikingly, while the production of CD244+/Nkp46+ (immature NK cells) and CD244+Nkp46− (NK cell progenitors) cells was significantly accelerated in Smad3−/− or SIS3-treated Smad3+/+ bone marrow cells, this promoting effect was diminished when E4BP4 was knocked down (Fig. 4e,f), demonstrating the functional importance of E4BP4 in the Smad3-mediated NK cell differentiation. Furthermore, a reversed Smad3-binding site (SBS) was found within the 3′ UTR (untranslated region) of E4BP4 gene (Fig. 4g) by using ECR browser (rVista 2.0, http://rvista.dcode.org/)27. The physical binding of Smad3 on the UTR of E4BP4 gene was enriched by TGF-β1 stimulation as shown by the results of chromatin immunoprecipitation (ChIP) assay (Fig. 4h,i). Thus Smad3 transcriptionally inhibited E4BP4 in response to TGF-β1, which was reversed when Smad3 is mutated as demonstrated by the luciferase reporter assay (Fig. 4j). These findings revealed the inhibitory role of Smad3 in NK cell development via downregulating the transcription of its direct target gene E4BP4. Given that deficiency of Smad3 prevents TGF-β1-mediated inhibition of E4BP4 expression, targeting the TGF-β1/Smad3–E4BP4 axis to accelerate the development of NK cells may enhance their anticancer immunity within the tumour microenvironment.

**Targeting Smad3 protects against cancer progression.** The encouraging findings from tumour-bearing Smad3−/− mice leads us to further test a hypothesis that targeting Smad3-dependent tumour microenvironment may protect mice against cancer progression. This was examined on Smad3+/+ mice bearing B16F10 or LLC tumours by inactivating Smad3 signalling with an inhibitor SIS3 that specifically blocks the phosphorylation and DNA binding of Smad3 proteins29. The systemic treatment of SIS3 significantly inhibited the phosphorylation of Smad3 in both LLC and B16F10 tumour tissues and suppressed cancer progression in a dosage-dependent manner, resulting in a 100% survival rate (Figs 6a–d and 7a and Supplementary Figs 11A–D and 12A). More importantly, SIS3 treatment significantly increased NK cell production in a dose-dependent manner, showing up to a fivefold increase in Nkp46+ cells in tumour tissues (Fig. 6e). Inhibition of Smad3 also enhanced anticancer activities of NK cells by increasing releases of granzyme B, IL-2 and IFN-γ locally within the tumour tissues and systemically in the circulation (Fig. 6f,g). Depletion of NK cells from SIS3-treated B16F10 tumour-bearing mice partially reversed the antitumour effects of SIS3 (Supplementary Fig. 13), which further supports the promoting role of Smad3-mediated NK suppression in cancer progression. In *in vitro* study also confirmed this finding that pharmacological inhibition of Smad3 signalling with a SIS3 was capable of enhancing cancer-killing activities in both bone marrow-derived or splenic NK cells (Supplementary Fig. 8A,B). We demonstrated that the enhanced NK cell-mediated anticancer immunity has an important role in the anticancer effects of Smad3-dependent tumour microenvironment targeted treatment. Furthermore, systemic treatment of SIS3 also significantly altered the tumour-friendly microenvironment, including suppression on angiogenesis (VEGF expression and CD31+ vessels) and tumour-invasive factors (MMP-2, MMP-9, MMP-13 and CXCR4) (Fig. 7b–d, Supplementary Fig. 12B–D). In *in vitro* treatment with SIS3 was also able to inhibit the proliferation of B16F10 melanoma cells in a dose-dependent manner (Supplementary Fig. 14) and this may also suggest a direct inhibitory effect of SIS3 on tumour cell growth. Taken together, our results revealed that targeting Smad3-dependent microenvironment may represent a novel and effective therapy for invasive cancer.

**Discussion**

TGF-β has a supportive role in progression of established tumour and Smad3 is a key mediator in the canonical TGF-β signalling pathway. However, the potential role of Smad3 in the TGF-β1-dependent tumour microenvironment remains incompletely characterized. In this study, we demonstrated that Smad3 is...
Figure 4 | Smad3 suppresses NK cell differentiation by downregulating E4BP4 in vivo and in vitro. (a) Western blotting analysis shows the expression of E4BP4 in the NK cells isolated from the bone marrow and spleen of the B16F10 tumour-bearing Smad3\(^{+/+}\) and Smad3\(^{-/-}\) mice on day 10 after tumour inoculation. (b) Real-time PCR detects the effect of TGF-β1 (1 ng ml\(^{-1}\)) on the transcription of E4BP4 in Smad3\(^{+/+}\) and Smad3\(^{-/-}\) bone marrow cells at 3 h. (c,d) Effect of SIS3 (2 μM) on TGF-β1-mediated E4BP4 mRNA expression in bone marrow or spleen-derived NK cells. (e) Two-color flow cytometry detects the effects of knockdown of E4BP4 and deletion (Smad3\(^{-/-}\)) or inhibition (SIS3) of Smad3 in the production of bone-marrow cell derived CD244\(^+\) NKp46\(^+\) (NK progenitor) and CD244\(^+\) NKp46\(^+\) (immature NK) cells (upper panels) on Day 6. (f) Quantitative results of CD244\(^+\) cells from flow cytometry analysis. (g) A predicted SBS at the 3' UTR of the evolutionarily conserved region of E4BP4 in human and mouse genomes (upper panel), indicated by bold and underlined (lower panel). (h,i) ChIP assay was performed with Smad3\(^{+/+}\) bone marrow cells stimulated with TGF-β1(1 ng ml\(^{-1}\)) and the enrichment of Smad3 binding to the 3' UTR of E4BP4 gene was qualified by PCR (h) and quantified by real-time PCR (i). (j) Dual luciferase assay shows the inhibitory effect of Smad3 binding on E4BP4 3' UTR reporter activity. Data represent mean ± s.e.m. for three independent experiments, *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group (b-d,i) or Smad3\(^{+/+}\) cells (a,f); #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the TGF-β1-treated group (c,d), individual controls (f) or E4BP4-mutant (j) analysed by analysis of variance.
essential for TGF-β1-mediated cancer progression, as both genetic deletion and pharmacological inhibition of Smad3 produced a significant inhibition of cancer growth, invasion and metastasis, resulting in a markedly improved survival rate in mouse models of LLC lung cancer and B16F10 melanoma. Increase in production and antitumor activities of NK cells but decrease in angiogenesis, Treg response and tumour-invasive activities were found in the Smad3-knockout or -inhibited tumour-bearing mice. It is suggested that TGF-β1-mediated pro-tumorigenic microenvironment can be shifted into a

Figure 5 | The antitumor effect of Smad3−/− NK cells is dependent on E4BP4 more than on T-bet. (a) Saline (Control), nonsense-treated Smad3+/+ (Smad3+/+ NK), nonsense-treated Smad3−/− (NC) NK cells or Smad3−/− NK cells with E4BP4 knockdown (siE4BP4) or T-bet knockdown (siT-bet) were infused (i.v.) into B16F10 tumour-bearing NOD/SCID mice and the antitumour effects are qualified by imaging on day 10 after NK cell infusion. (b) Tumour weight after NK cell infusion on day 10. (c) Tumour-associated NK cells detected by two-colour immunofluorescence with the anti-NK1.1 and anti-CD3 antibodies (scale bars, 100 μm). Note that most of anti-NK1.1+ cells within the tumour microenvironment are negative for CD3. (d,e) Effect of E4BP4 and T-bet on ex vivo NK differentiation in Smad3+/+ or Smad3−/− bone marrow cells on day 7. Bone marrow cells were transfected with siE4BP4 or siT-bet and the NK cell population in B16F10 tumour was detected by western blotting with NKp46 (d) or by two-colour flow cytometry with the anti-NKp46 and IFN-γ antibodies (e). Data represent mean ± s.e.m. for groups of three mice or at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group (b, d) or Smad3+/+ NK cells (e); #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the S3WT-NK group; &P < 0.05 and &&P < 0.01 compared with the siE4BP4 group analysed by analysis of variance.
Figure 6 | Inhibition of Smad3 prevents cancer progression by restoring NK cell anticancer immunity in tumour-bearing Smad3+/− mice. B16F10-luc cancer cells were s.c. inoculated into Smad3+/− mice and followed by treatment with various dosages of SIS3 (0, 2.5, 5.0 or 10 μg g−1 day−1, i.p.). (a) Representative bioluminescent images of the B16F10-luc tumours, (b) tumour volumes, (c) tumour weights on day 15 after treatment, (d) survival rates and (e) representative immunofluorescent images of tumour sections stained with the anti-NKp46 antibody (red) on day 15 after treatment. Nuclei were counterstained with DAPI (blue). (f,g) Enzyme-linked immunosorbent assay detects the levels of granzyme B, IL-2 and IFN-γ in the tumour tissues (f) and circulation (g) on day 15 after SIS3 treatment. Data represent mean ± s.d. for groups of 4–6 mice. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control (saline-treated) analysed by analysis of variance. Scale bars, 100 μm.
tumour-suppressive one by targeting the Smad3-dependent tumour microenvironment. We demonstrated that Smad3 is an important checkpoint for TGF-β-mediated cancer progression in the tumour microenvironment. Therefore, targeting Smad3-dependent tumour microenvironment may represent a novel and effective anticancer therapy.

Several mechanisms may be associated with the promoting effect of Smad3-dependent microenvironment on cancer progression, including angiogenesis, Treg response and tumour-invasive factors, as well as availability of NK cells. We found that genetic deletion or pharmacological inhibition of Smad3 significantly enhanced the production of NK cells (NK1.1+/NKp46+) locally in the tumour microenvironment and systemically in the peripheral blood and splenic tissue. The effect of Smad3+/− microenvironment on NK cell production was confirmed on a B16F10-rechallenged model, where increased

Figure 7 | SIS3 treatment suppresses angiogenesis and the expression of tumour-invasive factors in B16F10 tumour-bearing Smad3+/+ mice.
Western blotting analysis shows the intratumoral phosphorylation of Smad3 (a), angiogenesis including the expression of VEGF and CD31 proteins (b), pro- and active MMP-2, MMP-9 and MMP-13 expression (c) and CXCR4 expression (d) of the SIS3-treated mice. Data represent mean ± s.e.m. for groups of 4–6 mice. *P<0.05, **P<0.01, ***P<0.001 compared with the control-treated group analysed by analysis of variance.
of Smad3 also enhanced the production of NKp46. This was further confirmed by in vitro finding that deletion of Smad3 also enhanced the production of NKp46. The role of TGF-β was also demonstrated by depleting NK cells from tumour-bearing Smad3+/− mice with a neutralizing anti-NK1.1 antibody to restore the aggressive progression of melanoma. However, the use of anti-NK1.1 antibody may also deplete NKt cells; therefore, the specific role of Smad3 in NK cell production was further examined by adoptive transfer of Smad3+/− or Smad3+/+ NK cells (NK1.1+) into the tumour-bearing NK cell deficiency mice (NOD/SCID). We demonstrated an enhanced anticancer effects of Smad3+/− NK cells in cancer progression whereby mice infused with Smad3−/− NK1.1+ cells displayed reduced tumour growth compared with Smad3+/+ NK1.1+ cell-recipient mice. It has been reported that TGF-β can inhibit NK cell-mediated anticancer immunity, including maturation, cytotoxicity, IFN-γ production and the expression levels of activating receptors NKGD2 and NKp46 (refs 15–17, 30–34). TGF-β can also suppress CD16-mediated NK cell IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells via Smad3 (refs 17). Our findings reveal an unexplored role of Smad3 in the suppression of NK cell production and activities. Results from this study may also provide insights to explain the observation that NK cell development and activities are largely impaired in patients with cancer.

Another novel finding from this study was that TGF-β1 can directly induce the cancer cell immunity via a Smad3–E4BP4 axis and facilitate the cancer progression. E4BP4 (NFIL3) is one of the important master transcription factors for NK cell differentiation22–24. Here we found that TGF-β1 downregulated E4BP4 expression in the bone marrow- and spleen-derived NK cells in a Smad3-dependent manner, whereas genetic deletion or pharmacological inhibition of Smad3 successfully inhibited the TGF-β1-mediated E4BP4 suppression in NK cells. More importantly, we identified that E4BP4 is a direct Smad3 target gene. The conserved SBS located in the UTR of E4BP4 gene was validated by ChIP assay. Smad3 could physically bind to the E4BP4 gene and negatively regulate its transcription in response to TGF-β1, which was further confirmed by the real-time PCR and luciferase reporter assays. The Smad3-mediated suppression of E4BP4 was functionally important not only in NK cell development but also in the cancer-killing activity. Knockdown of E4BP4 decelerated the differentiation of both CD244+ NKp46+ (immature NK cells) and CD244+ NKp46− (NK cell progenitors) and also reduced the expression of INF-γ of NK cells from either Smad3+/− or Smad3+/+ bone marrow cells. Interestingly, comparing to the study with transfer of Smad3−/− T-bet knockdown NK cells, adoptive transfer of Smad3−/− E4BP4 knockdown NK cells significantly promoted tumour growth in NOD/SCID mice with lower levels of INF-γ production. This suggested that E4BP4 may be a more important transcriptional factor than T-bet in NK cell development and functions. The ability of adoptive transfer of E4BP4 knockdown Smad3−/− NK cells to reverse the suppressive effect of Smad3−/− NK cells on tumour growth in B16F10 tumour-bearing NOD/SCID mice revealed the specific role of E4BP4 in NK cell-mediated antitumour activities. This finding is consistent with a previous study that deletion of T-bet did not alter the INF-γ expression by NK cells in response to parasitic infection37. A direct E4BP4-binding site can be predicted on the promoter of IFN-γ and the transcription of IFN-γ can be reduced in Smad3−/− NK cells by E4BP4 knockout in a T-bet independent manner. Therefore, it is suggested that E4BP4 may be one of the possible candidates of T-bet-independent pathway for Smad3-mediated NK cell immunity. Our study demonstrated that Smad3-mediated inhibition of E4BP4 transcription may be a critical mechanism by which deletion of Smad3 promotes NK cell immunity and suppresses cancer progression. Nevertheless, further investigations should be done to confirm the T-bet independent pathway of TGF-β/Smad3-mediated suppression on NK cell immunity.

Interestingly, we found that a majority of NK cells in the Smad3−/− tumour microenvironment originated from bone marrow, as significant induction of GFP+ NK1.1+ NK cells was observed in the tumour tissues of the chimeric GFP+ Smad3−/− mice. Bone marrow is a primary site for NK cell development, and it offers the cellular substrates and soluble factors required for NK cell maturation38. NK cells can migrate from the bone marrow to peripheral lymphoid organs, such as the spleen and lymph nodes38. NK cells exert promising anticancer activity, which may be circumvent by tumour-friendly microenvironment via TGF-β/Smad3 signalling as defined in the present work. In line with this notion, we found that cancer cells (B16F10 and LLC) proliferated at the same rate in both Smad3+/+ and Smad3−/− mice during the first week after tumour implantation, but the progression was dramatically inhibited in the Smad3−/− mice from week 2 onwards. This interesting phenomena implies that the host anticancer immunity, presumably NK cells derived from bone marrow, was exclusively suppressed in the Smad3+/+ mice after the tumour was fully established; but this suppressive effect can be abolished when Smad3 was deleted or inhibited in the tumour microenvironment. This may explain the dramatic increase in GFP+ NK1.1+ NK cells at the tumour stroma of the GFP+ Smad3−/− chimeric mice. These findings also indicate that NK cell development can be strongly suppressed in the bone marrow compartment of Smad3+/+ microenvironment during cancer progression, but it can be restored if Smad3 is eliminated. Thus Smad3 may function as a determining factor for NK cell development in the bone marrow, possibly via the TGF-β1/Smad3–E4BP4 axis as discovered in this study.

Besides the enhanced NK cell immunity, we also observed that upregulation of angiogenesis markers (for example, VEGF and CD31+ vessels) and cancer invasive and metastatic proteins (for example, MMP-2, MMP-9, MMP-13 and CXCR4) were largely inhibited in the tumour microenvironment of Smad3−/− mice and in Smad3+/+ mice treated with SIS3. These findings were consistent with the reported properties of TGF-β/Smad3 signalling in the induction of VEGF and MMP expression39,40. It is well documented that both angiogenesis and cancer invasive and metastatic activities play a critical role in cancer progression41–43. Therefore, inhibition of angiogenesis and tumour-invasive activities may account for the additional anticancer mechanism by disrupting Smad3 in the tumour microenvironments. Furthermore, inhibition of CD4+ Foxp3+ Treg cells could be another mechanism associated with enhanced NK cell immunity in the tumour-bearing Smad3−/− mice. It is well accepted that Smad3 is an important transcriptional factor that binds to Foxp3 and facilitates Treg development12,13. It is also reported that Treg cells within the tumour microenvironment can suppress cytotoxicity of NK cells, which is reversed by Treg targeted treatment44,45. Thus it is likely that enhancement of NK cell-mediated anticancer immunity may be associated with inhibition of Treg cells in the Smad3−/− tumour microenvironment. However, the precise mechanism needs to be further investigated.
Moreover, the present study also demonstrated that targeting Smad3-dependent tumour microenvironment may represent a novel and effective anticancer therapy. By using a SIS3 that specifically inhibits phosphorylation, DNA binding and protein interaction of Smad3, we demonstrated that systemic treatment with SIS3 (2.5, 5, 10 μg/g, i.p., daily) successfully blocked the Smad3 activation in the tumour microenvironment and significantly suppressed the tumour growth and invasion and associated with a 100% overall survival rate in the B16F10 and LLC tumour-bearing Smad3+/+ mice. In line with the observations in the Smad3−/− mice, SIS3 treatment also markedly enhanced the development and anticancer activities of NK cells via a E4BP4-dependent mechanism. This was supported by the finding that SIS3 treatment was capable of increasing E4BP4 expression in Smad3+/+ bone marrow and NK cells and reversed the suppressive effect of Smad3 on NK cell development.

In addition, the suppressive effect of SIS3 on cancer progression was also associated with inhibition of angiogenesis (CD31 and VEGF) and tumour-invasive and metastatic activities, including the expression of MMP-2, MMP-9, MMP-13 and CXCR4. It is also possible that direct cytotoxicity of SIS3 on cancer cells in vitro may account for an additional antitumour effect of SIS3 in vivo. The findings suggested SIS3 as a potential checkpoint inhibitor for cancer. Thus systemic Smad3-targeted therapy may represent a novel and effective therapeutic strategy for invasive cancer.

In conclusion, Smad3-dependent tumour microenvironment plays a crucial role in cancer growth, invasion and metastasis. TGF-β establishes its tumour-friendly microenvironment by suppressing NK cell production and cancer-killing activity via a Smad3–E4BP4 axis. Our findings suggest that modulating the TGF-β-dependent tumour microenvironments by targeting Smad3 may represent an effective anticancer therapy.

Methods

Establishment of LLC-luc and B16F10-luc tumour cell lines. The murine lung adenocarcinoma LLC (CRL-1642, ATCC) and melanoma B16F10 (CRL-6475, ATCC) cells were cultured in DMEM supplemented with 10% heat-inactivated FCS (GIBCO-BRL), 1 μM sodium pyruvate, 2 mM glutamine, 100 U/ml penicillin G and 100 μg/ml streptomycin. The luciferase overexpression stable cell lines of LLC-luc and B16F10-luc were established by transfection of pBRL-CMV lentiviral-luciferase vector into the cancer cells, followed by clone selection.

Syngeneic mouse tumour models. Littermate Smad3−/− (deletion of exon 8 and disruption of exon 7) or Smad3+/+ mice on C57BL/6 (H-2b) background (both sexes, aged 6–8 weeks, 20–25 g) were kindly provided by Dr Chunia Deng10 and were used in this study. Two syngeneic mouse tumour models were induced in Smad3−/− and Smad3+/+ mice by subcutaneously (s.c.) inoculating 2×106 LLC-luc or B16F10-luc cells (both from C57BL/6 mice) into the right flank of the mouse. To confirm tumour rechallenge model, first B16F10 tumour were induced in Smad3−/− and Smad3+/+ mice by s.c. inoculating 1×106 B16F10-luc cells into the left flank of the mice, and the established tumours were surgically removed on Day 15. Three weeks after, second B16F10 tumours (1×106 cells per mouse, s.c.) were induced on the right flank of the same mice, tumour volumes were monitored and samples were collected on Days 15 and 20 for further analysis. According to the protocol of Zaharoff et al.48. For metastasis study, 3×105 of LLC-luc or B16F10-luc cells were i.v. administered into Smad3−/− and Smad3+/+ mice. The number and volume of surface nodules of B16F10 melanoma (dark black) in the lung of each mouse were counted, while LLC-luc tumours were observed by bioluminescence imaging with IVIS Spectrum system (Caliper, Hopkinton, MA). The photon intensity from specific regions was quantified by using the Living Imaging software 4.2 (PerkinElmer). The tumour size was monitored every week with a Vernier caliper and tumour volume was calculated by the formula: 

\[ V = \frac{4}{3} \pi (a \times b^2) \]

where a is the long diameter and b is the short diameter as previously described48. The raw data underlying the tumour volume measurements are shown in Supplementary Data 1. Mice were observed daily for the weight loss, distress, food intake and activities. Mice were killed before the end point if >20% weight loss occurred or the tumour reached the maximum permitted size (2000 mm³), but experiments could be extended under veterinary supervision under special circumstances, for example, if tumours grew faster than expected. The specific experimental approach and the data obtained have been reviewed by the Animal Ethics Experimental Committee at the Chinese University of Hong Kong and confirmed to be in accordance with local regulations. The survival rate was recorded over the entire experimental period and converted into prolonged survival following the Kaplan–Meier method49. All experimental procedures were approved by the Animal Ethics Experimental Committee at the Chinese University of Hong Kong (No. 13/049/GFR).

Tumour model in GFP-expressing bone marrow chimeric mice. To determine the origin and role of Smad3-dependent tumour microenvironments in cancer progression, GFP+/Smad3−/− and GFP+/Smad3+/+ bone marrow–chimeric mice were generated by cross-breeding Smad3−/−/C57BL/6j mice with GFP transgenic C57BL/6j mice. A lethally irradiated (1500 rad) wild-type mouse was reconstituted with 1×10⁶ bone marrow cells from the GFP+/Smad3−/− or GFP−/Smad3+/+ mice. Mice were generated by cross-breeding Smad3+/−/C2 mice and Smad3−/−/C2 mice (No. 13/049/GFR and 13/025/MIS). The survival rate were measured as described in the section on syngeneic tumour models. All experimental procedures were approved by the Animal Ethics Experimental Committee at the Chinese University of Hong Kong (No. 13/049/GFR).

NK cell depletion and adoptive transfer models. For depletion of NK cells, Smad3−/− and Smad3+/− mice were pretreated with the anti-NK1.1 (PK136, BioXCell) or immunoglobulin G1 (IgG1) as negative control antibody (200 μg per mouse, i.p.) at Day 1. Then B16F10-luc cells (2×10⁶ cells) were s.c. inoculated into groups of five mice with or without NK1.1− cell depletion on Day 0, followed by three additional antibody treatments (200 μg per mouse, i.p., weekly). The efficiency of NK cell depletion was confirmed with the absence of CD49b+ cells (staining with anti-CD49b antibody, DX5, eBioscience) by flow cytometric analysis of small blood samples collected from the tail vein of antibody-treated mice.

To determine the specific role of Smad3-dependent NK cell antitumour activities, a B16F10 tumour-bearing NOD/SCID mouse model45.50 was adoptively transferred with Smad3−/− or Smad3+/− NK cells (NK1.1+). Briefly, B16F10 cells (1×10⁶ cells) were inoculated i.c. into groups of three NOD/SCID mice in which both NK and NK T cells are deficient. After tumour establishment on Day 5, Smad3−/−/NK1.1+ or Smad3+/−/NK1.1+ cells (5×10⁶ cells) were infused i.v. into the B16F10 tumour-bearing NOD/SCID mouse every 5 days with IL-2 supplement (i.p., 1,000 U per mouse) every 2 days for examining tumour growth and NK cell antitumour activities on Day 10. In addition, we compared the relative antitumour activities of E4BP4 versus T-bet-dependent NK cells by adoptive transfer of siE4BP4-Smad3−/− or siT-bet-Smad3−/−/NK1.1− NK cells (5×10⁶ cells) into B16F10 tumour-bearing NOD/SCID mice as described above for examining tumour growth and NK cell antitumour activities. The raw data underlying the tumour volume measurements are shown in Supplementary Data 1. The animals were observed daily and the tumour size and survival rate were measured as described in the section on syngeneic tumour models. All experimental procedures were approved by Animal Ethics Experimental Committee at the Chinese University of Hong Kong (No. 13/049/GFR and 13/025/MIS).

SIS3 treatment. The tumour-bearing Smad3+/+ mice were randomly divided into four groups (n=8 each group) on Day 7 after LLC-luc or B16F10-luc cancer cell (s.c.) inoculation. SIS3 (0.047g, Sigma) at different dosages (2.5, 5 or 10 μg/g, i.p., daily) were administered into the mice for 2 weeks, whereas control group were received solvent control (0.05% dimethyl sulfoxide) instead. Tumour size was monitored with a Vernier caliper every 2 day during the treatment. All mice were subjected to bioluminescence imaging and then killed after the survival rate was recorded on 15 days after SIS3 treatment. To determine the role of NK cells in SIS3-mediated tumour suppression, NK cell depletion was done on SIS3-treated mice and compared the result with SIS3-treated IgG control group on Day 15.

The tumours were isolated, weighted and photo-recorded. Tumour tissues were collected for further analysis. The raw data underlying the tumour volume measurements are shown in Supplementary Data 1. The animals were observed daily and the tumour size and survival rate were measured as described in the section on syngeneic tumour models. All experimental procedures were approved by Animal Ethics Experimental Committee at the Chinese University of Hong Kong (No. 13/025/MIS).

NK cell isolation. Splenic and bone marrow NK cells of the tumour-bearing mice were harvested by passing the cells through a 40 μm nylon mesh to produce a single-cell suspension. Erythrocyte contamination was eliminated by using RBC lysis buffer (BioXCell). After lysis, NK cells were isolated using mouse anti-rat CD49b monoclonal antibody (BioXCell) and magnetic-activated cell sorting (MACS) Kit II (Miltenyi Biotec), which provided 90–95% purity of NK cells as determined by flow cytometry with CD3+CD49b+ cells.
Flow cytometric analysis. For quantitative analysis of NK cell populations, tissue samples of the tumour-bearing mice were mechanically dissociated in chilled PBS (supplemented with 3% BSA) and gently mashed through a 40-μm nylon mesh to produce a single-cell suspension. NK cell populations were analysed with a flow cytometer by staining with Alexa 488-conjugated anti-mouse CD49b (DX5, eBioscience), PE-conjugated anti-mouse NK1.1 (PK136, eBioscience), Cy3-conjugated anti-mouse NKp46 (bs-2417R-cy3, Bioss) and PE-conjugated anti-mouse CD244 (12-2441-83, eBioscience) antibodies. For IFN-γ analysis, NK cells (1 × 10^6) were cultured in the presence of 2 μM monensin (eBioscience) and then fixed and stained intracellular IFN-γ (eBioscience) for 5 h. The samples were subjected to acquire on FACSAgilent (Becton Dickinson) and analysed with the WinMDI 2.9 software and Cytobank platform (cytobank.org).

NK cell cytotoxicity assay. The anticancer activity of NK cells was evaluated by using a Cell-TooX Bioluminescence Cytotoxicity Assay Kit (Cell Technology Inc.). In brief, isolated splenic NK cells from the tumour-bearing Smad3^−/− or Smad3^+/+ mice were incubated with the NK-sensitive target cells (YAC-1), syngeneic LLC or B16F10 cells at ratios of 1:25:1, 2:5:1, 5:1 and 20:1, respectively. In addition, splenic NK cells isolated from normal Smad3^−/− mice activated with the CEA, VEGF, MMP-2, MMP-9, MMP-13, CXCR4, NKp46, p-Smad3, Smad3 (all from Santa Cruz Biotechnology) and E4BP4 (Cell Signaling) in 1:1,000, followed by incubation with the corresponding IRDyeTM800-conjugated secondary antibodies (1:10,000, Rockland Immunochemicals). β-Actin was used as an internal control. Expression levels of the proteins were detected by using LiCor/Odyssey infrared image system (LI-COR, Biosciences), and the band intensities were quantified with the Image J software (version 1.48, NIH, Bethesda). Images have been cropped for presentation; their full size images are presented in Supplementary Figs 15–20.

Histology and immunohistochemistry. For immunohistochemistry, tumour tissues embedded in Optimal Cutting Temperature were cut into 6 μM sections and stained with the specific antibodies. The microvessels of tumour tissues were detected by immunofluorescence with primary antibodies against CD31, VEGF, MMP-2, MMP-9, MMP-13, CXCR4, NKp46, p-Smad3, Smad3 (all from Santa Cruz Biotechnology) and E4BP4 (Cell Signaling) in 1:1,000, followed by incubation with the corresponding IRDyeTM800-conjugated secondary antibodies (1:10,000, Rockland Immunochemicals). β-Actin was used as an internal control. Expression levels of the proteins were detected by using LiCor/Odyssey infrared image system (LI-COR, Biosciences), and the band intensities were quantified with the Image J software (version 1.48, NIH, Bethesda). Images have been cropped for presentation; their full size images are presented in Supplementary Figs 15–20.

Enzyme-linked immunosorbent assay. Levels of plasma and intratumoural granulocyte B, IL-2 and IFN-γ were determined by using the commercial enzyme-linked immunosorbent assay kits (eBioscience). To collect the intratumoural tissue fluids, the chilled PBS was added into each tumour tissue samples in a ratio of 1:100 mg tissue per ml. The tissues were then homogenized and centrifuged at 14,000 r.p.m. at 4 °C for 10 min. The collected tumour tissue solutions and blood plasma were subjected for determination of NK cell activities, including granulocyte B, IL-2 and IFN-γ, following the manufacturer’s instruction.

RNA extraction and real-time PCR. Total RNA was isolated from the cells using the RNasy Isolation Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Real-time PCR was performed using Bio-Rad iQ SYBR Green supermix with Option2 (Bio-Rad, Hercules, CA) as described previously. Primers used in this study included: E4BP4 forward 5’-cctgctagGTTGCTGGCAGGTATGC-3’ and E4BP4NotIR:5’-ataagagtgcgggcctgtGCGTGGCACCACACTTTTCT-3’ or (mut-E4BP4-F5’-GATGCCTCCTCCTGCTGTTGAGTTT-3’ and mut-E4BP4-R5’-AGTATGTACAGCC-3’) into the psiCHECK-2 vector. In addition, a pair of overexpression plasmids was constructed with the cDNA of Smad3 (GenBank Accession no. AF432070) and IgG was used as a control (Cell Signaling). Precipitated DNAs were identified by PCR using specific primers that detect the binding of Smad3 to 3’UTR of mouse E4BP4 gene: forward 5’-CTCTGACACATGGAGAGG-3’ and reverse 5’-CGGAACAAGCTGATCCCG-3’.

Luciferase reporter assay of E4BP4 3’UTR. Construction of reporter vectors and mutant plasmids and luciferase assays were performed by Labiomed (Guangzhou, China). For E4BP4 3’UTR reporter, a pair of reporter plasmids was constructed with the SBS in E4BP4 3’ UTR or its mutant by inserting the following oligos (E4BP4XhoI: 5’-ccctgctagGTTGCTGGCAGGTATGC-3’) and E4BP4NotIR:5’-ataagagtgcgggcctgtGCGTGGCACCACACTTTTCT-3’ or (mut-E4BP4-F5’-GATGCCTCCTCCTGCTGTTGAGTTT-3’ and mut-E4BP4-R5’-AGTATGTACAGCC-3’). Luciferase activity (M1) and Renilla luciferase activity (M2) were measured by GloMax-Multi Detection System (Promega). The ratio for M1/M2 was calculated according to the manufacturer’s instructions. The luciferase activity (M1) and Renilla luciferase activity (M2) were measured by GloMax-Multi Detection System (Promega). The ratio for M1/M2 was calculated according to the manufacturer’s instructions. The luciferase activity (M1) and Renilla luciferase activity (M2) were measured by GloMax-Multi Detection System (Promega).

Statistical analysis. Statistical analysis of the differences in MT assay, tumour volume, tumour weight, photon intensity, ratios of tumour nodules and positive cells, protein and mRNA expression levels, dual luciferase reporter assay and NK cell cytotoxicity assays were performed using analysis of variance, following by Newman–Keuls Post Test from the Prism Program (Prism 5.0 GraphPad Software, San Diego, CA). Survival rates were generated based on the Kaplan–Meier method and statistical significance was determined by the log-rank test. P value <0.05 was considered statistically significant.

Data availability. All data are available within the article, as figure source data or Supplementary Information Files, or from the authors upon reasonable request.

References
1. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating cancer’s roles in cancer suppression and promotion. Science 313, 1565–1570 (2006).
2. Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment on therapeutic response. Nature 501, 346–354 (2013).
3. Derynck, R., Akhurst, R. J. & Balmain, A. TGF-beta in cancer. Nat. Rev. Cancer 14, 117–129 (2011).
4. Massagué, J. TGFbeta in cancer. Cell 134, 215–230 (2008).
5. Ikushima, H. & Miyazono, K. TGF-beta signaling: a complex web in cancer progression. Nat. Rev. Cancer 10, 415–424 (2010).
6. Piccolo, S., Novotny, M. V., S. & Moses, H. L. The roles of TGFβ in the tumor microenvironment. Nat. Rev. Cancer 13, 788–799 (2013).
7. Yang, L., Pang, Y. & Moses, H. L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31, 220–227 (2010).
8. Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Limón, P. The polarization of immune cells in the tumor environment by TGFbeta. Nat. Rev. Immunol. 10, 554–567 (2010).
9. Datto, M. B. et al. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol. Cell Biol. 19, 2495–2504 (1999).
10. Yang, X. et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 18, 1280–1289 (1999).
11. Giroux, M. et al. SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediates tissue damage. Blood 117, 1734–1744 (2011).
12. Schlenner, S. M., Weigmann, B., Ruan, Q., Chen, Y. & von Boehmer, H. Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. J. Exp. Med. 209, 1529–1535 (2012).
13. Martinez, G. J. et al. Smad3 differentially regulates the induction of regulatory and inflammatory T cell differentiation. J. Biol. Chem. 284, 35283–35286 (2009).
14. Guo, A. D., Wang, Y., Lin, L., Zhang, S. S. & Wan, Y. Y. Requirements of transcription factor Smad-dependent and -independent TGF-beta signaling to control discrete T-cell functions. Proc. Natl Acad. Sci. USA 109, 905–910 (2012).
15. Rook, A. H. J. et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136, 3916–3918 (1986).
16. Bellone, G., Aste-Amezaga, M., Trinchieri, G. & Rodeck, U. Regulation of NK cell functions by TGF-beta 1. J. Immunol. 155, 1066–1073 (1995).
17. Trotta, R. et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 181, 3784–3792 (2008).
18. Zhu, Y., Richardson, J. A., Parada, L. F. & Graff, J. M. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94, 703–714 (1998).
19. Maggio-Price, L. et al. Helicobacter infection is required for inflammation and colon cancer in Smad3-deficient mice. Cancer Res. 66, 828–838 (2006).
20. Maggio-Price, L. et al. Bacterial infection of Smad3/Rag2 double-null mice with transforming growth factor-beta disregulation as a model for studying inflammation-associated colon cancer. Am. J. Pathol. 174, 317–329 (2009).
21. Li, A. G., Lu, S. L., Zhang, M. X., Deng, C. & Wang, X. J. Smad3 knockout mice exhibit a resistance to skin chemical carcinogenesis. J. Invest. Dermatol. 128, 589–596 (2006).
22. Kamizono, S. et al. Targeted disruption of SMAD3 reveals an essential role in immunity and diminished T cell responsiveness to TGF-beta. J. Immunol. 147, 1359–1370 (2001).
23. Zafar, H. et al. Overactivation of the TGF-beta pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology 58, 2032–2044 (2013).
24. Ghiringhelli, F. et al. CD4 + CD25 + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 202, 1075–1085 (2005).
25. Jie, H. B. et al. CTLA-4 + Regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 75, 2200–2210 (2015).
26. Zaharoff, D. A., Hance, K. W., Rogers, C. J., Schlom, J. & Greiner, J. W. Intratumoral immunotherapy of established solid tumors with citosin/IL-12. J. Immunother. 33, 697–7052010 (2010).
27. Zhou, S. et al. Combination therapy of YVEG-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model. PLoS ONE 8, e65839 (2013).
28. Zhou, S. et al. CCR7 expression and intratumoral FOXP3 + regulatory T cells correlate with overall survival and lymph node metastasis in gastric cancer. PLoS ONE 8, e74430 (2013).
29. Kataoka, S. et al. Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity. Diabetes 32, 247–253 (1983).
30. Kim, E. et al. Abnormalities of cellular immunity. Diabetes 32, 247–253 (1983).
31. Zhang, J. et al. Autocrine growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 124, 1081–1088 (2014).
32. Moller, N., Semple, J. P., Welch, R. W. & Folkman, J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1–8 (1991).
33. Meng, X. M. et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J. Am. Soc. Nephrol. 21, 1477–1487 (2010).
34. Zhou, Q., Huang, X. B., Yu, J., Yu, X. & Lan, H. Y. Long noncoding RNA Arid2-IR is a novel therapeutic target for renal inflammation. Mol. Ther. 23, 1034–1043 (2015).
35. Fathman, J. W. et al. Identification of the earliest natural killer cell-committed progenitor in murine bone marrow. Blood 118, 5439–5447 (2011).

Acknowledgements

We thank Dr Chuxia Deng for Smad3−/− mice. This study was supported by the Research Grants Council of Hong Kong (GRF 469110, 468711, CUHK3/CRF/12R), Innovation and Technology Fund of Hong Kong (ITS/227/15), the Focused Investment Scheme A from Chinese University of Hong Kong and Hong Kong Scholar Program.

Author contributions

P.K.-K.T., S.Z. and X.-M.M. have contributed equally to this work. H.-Y.L. designed and supervised all experiments and contributed to manuscript preparation. P.K.-K.T. and X.-M.M. conducted all experiments, analyzed data and contributed to manuscript preparation. Q.-M.W., G.-Y.L. and C.-J.L. collected animal samples and participated in animal experiments. X.-R.H., Y.-T.J., X.-Y.G., B.P.Y. and K.-F.T. contributed to data analysis and manuscript preparation.
